Bristol Stock Today

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
Bristol Myers is trading at 58.91 as of the 2nd of July 2020; that is -0.88 percent decrease since the beginning of the trading day. The stock's open price was 59.43. Bristol Myers has about a 31 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 30 trading days. Equity ratings for Bristol Myers Squibb are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 3rd of April 2020 and ending today, the 2nd of July 2020. Please note, there could be an existing legal relationship between Bristol Myers Squibb (BMY) and Bristol Myers Squibb (BMY.R). Click here to learn more.
Analyze Filter   Report: 6th of August 2020

   Performance
5 100 

   Odds of Distress
31  

Bristol Myers Profile

Upcoming quarterly report is expected on the 6th of August 2020. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people. more on Bristol Myers
Bristol Myers Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Bristol Myers Squibb SEC Filings
Bristol Myers SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameBristol Myers Squibb
Related EntityBMY.R (Bristol Myers Squibb)
PresidentAnn PowellView All
Thematic Classifications
Active investing themes Bristol Myers currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
showing 2 out of 4 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Bristol Myers Squibb. The Bristol consensus assessment is calculated by taking the average estimates from all of the analysts covering Bristol Myers
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Bristol Myers Squibb financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.6 B1.6 B
Sufficiently Down
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.9 B1.7 B
Significantly Up
Increasing
Stable
Net Cash Flow from OperationsB8.1 B
Fairly Down
Increasing
Slightly volatile
Total Assets140.2 B129.9 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities84.4 B78.2 B
Significantly Up
Increasing
Slightly volatile
Current Assets24.5 B29.4 B
Fairly Down
Increasing
Slightly volatile
Current Liabilities15.2 B18.3 B
Significantly Down
Increasing
Slightly volatile
Total Debt50.4 B46.7 B
Significantly Up
Increasing
Slightly volatile
Return on Average Assets0.07260.05
Way Up
Decreasing
Slightly volatile
Gross Margin0.670.691
Sufficiently Down
Decreasing
Slightly volatile
Asset Turnover0.440.377
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Bristol Myers available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Cautious HoldUndervalued
Financial Strength
Bristol Myers financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Bristol Myers success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
A+ ( Average Bond Rating ) Very Firm
  Operating Cash Flow
Bristol Myers Squibb (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 30,000 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with total capitalization of 81.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bristol Myers's market, we take the total number of its shares issued and multiply it by Bristol Myers's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Bristol Myers Squibb runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 1.64 B outstanding shares of which 30.59 M shares are currently shorted by investors with about 1.88 days to cover shorted positions. BRISTOL MYERS SQI has about 29.36 B in cash with 4.29 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.11.
Check Bristol Myers Probability Of Bankruptcy

Ownership Allocation (%)

Bristol Stock Price Odds Analysis

Odds Down 58.91HorizonTargetOdds Up 58.91
39.83%30 days
 58.91 
59.91%
Based on a normal probability distribution, the odds of Bristol Myers to move above the current price in 30 days from now is about 59.91 (This Bristol Myers Squibb probability density function shows the probability of Bristol Myers Stock to fall within a particular range of prices over 30 days) .

Bristol Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares198.9 M11.1 B
Blackrock IncCommon Shares170.5 M9.5 B
View Bristol Myers Diagnostics

Bristol Myers Income Statement Over Time

Bristol Myers Squibb Income Statement is one of the three primary financial statements used for reporting Bristol's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Bristol Myers Squibb revenue and expense. Bristol Myers Income Statement primarily focuses on the company's revenues and expenses during a particular period. Bristol Myers Consolidated Income is fairly stable at the moment as compared to the past year. Bristol Myers reported Consolidated Income of 3.46 Billion in 2019. Net Income to Non Controlling Interests is likely to grow to about 21.6 M in 2020, whereas Direct Expenses is likely to drop slightly above 6.5 B in 2020. View More Fundamentals

Bristol Stock Against Markets

Did you try this?

Run Price Exposure Probability Now

   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Bristol Myers Upcoming and Recent Events

Bristol Myers Company Earnings Announcements Dates

Upcoming Quarterly Report6th of August 2020
Next Earnings Report29th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End4th of February 2021
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

Bristol Myers Corporate Filings

Bristol Myers SEC Reporting

Financial Statements and Exhibits. Other Events
View
Other Events
View
Unclassified Corporate Event
View

Bristol Myers Distributions to stockholders

A dividend is the distribution of a portion of Bristol Myers earnings, decided and managed by the Bristol Myerss board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Bristol Myers dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
2nd of April 2020
2nd of January 2020
3rd of October 2019
3rd of July 2019
4th of April 2019
3rd of January 2019
4th of October 2018
5th of July 2018

Bristol Myers Corporate Directors

Togo West Independent Director
Karen Vousden Independent Director
Michael Bonney Independent Director
Continue to Trending Equities. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page